Država: Avstralija
Jezik: angleščina
Source: Department of Health (Therapeutic Goods Administration)
simoctocog alfa, Quantity: 250 IU
Octapharma Australia Pty Ltd
simoctocog alfa
Injection, powder for
Excipient Ingredients: sucrose; sodium chloride; sodium citrate dihydrate; poloxamer; calcium chloride dihydrate; arginine hydrochloride
Intravenous
1 vial
exempt from scheduling - Appendix A; prescription medicine
Treatment and prophylaxis of bleeding (also during and after surgery) in previously treated paediatric (>= 2 years) and adult patients with haemophilia A (congenital factor VIII deficiency). Nuwiq does not contain von Willebrand Factor and is thus not indicated to treat von Willebrand?s Disease.
Visual Identification: Nuwiq - white to off-white lyophilised powder,WFI - clear, colourless liquid; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 2 Years; Container Temperature: Store at 2 to 8 degrees Celsius
Licence status A
2014-11-10